CoChat
Sign Up
Cited by 5Diabetes Treatment and ManagementDiabetes Management and ResearchPharmaceutical Practices and Patient Outcomes

Clinical inertia in insulin prescription for patients with type 2 diabetes mellitus at a primary health care institution of Cartagena, Colombia

Open access
Llinás-Castro, Rodolfo, Alvis-Estrada, Luis, Durán-Lengua, Marlene·2018·Revista de la Facultad de Medicina
DOI 10.15446/revfacmed.v66n4.58933
Open this paper in CoChat — free account

Abstract

Introduction: Evidence has demonstrated clinical or prescriptive inertia along with an increased prescription of insulin, causing a delay in the change of prescription.Objective: To determine the prescription pattern and clinical inertia of insulin use in the treatment of patients with type 2 diabetes mellitus (DM2) enrolled in a diabetes program at a primary health care institution of Cartagena, Colombia.Materials and methods: Pharmacoepidemiology study that addresses drug utilization based on data collected through a review of medical records of 331 patients with DM2, aged 18 and older, who had at least 6 months of control.Results: 64.4% of patients were treated with long-acting insulin analogues and 18.4% used insulin; 52.7% of the patients in which insuline use was required did not have a prescription of this drug.Conclusions: There is clinical inertia related to insulin prescription. Strategies should be implemented to overcome prescriptive inertia for people with DM2 in order to achieve therapeutic goals earlier and effectively prevent the development and progression of chronic complications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15446/revfacmed.v66n4.58933

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Despite the development of new medications, a significant proportion of people with T2DM failed to achieve glycemic goal due to delayed stepping up in therapy by healthcare providers.

    “Despite the development of new medications over the past decades, a significant proportion of people with T2DM failed to achieve glycemic goal due to delayed stepping up in therapy by the healthcare providers [9].”

    From Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review (2023) · cites this paper as [9]

    The Introduction (page unavailable) describes clinical inertia: primary-care physicians often do not intensify treatment when glycemic goals are unmet, and may defer insulin even when HbA1c is elevated. The Discussion (page unavailable) also reports patients missing glycemic targets and patients with an indication for insulin who had not received it. The copy does not address the claim’s framing about the development of new medications over past decades. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 33 · Cited by 5

Part of this paper’s reference list could not be split into single entries.

Research works printed but not linked: 32

  1. [2]2. Gæde P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving H-H, et al. Cost-effectiveness of intensified versus conventional multi-factorial intervention in type 2 diabetes: results and projections from the steno-2 study. Diabetes Care. 2008;31(8):1510-5. http://doi.org/dh5v9j. [URL] 🠔
  2. [5]5. Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010;56(12):e418-24. 🠔
  3. [6]6. Tsai ST, Pathan F, Ji L, Yeung VT, Chadha M, Suastika K, et al. First in-sulinization with basal insulin in patients with Type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011;3(3):208-16. http://doi.org/bkc4tw. [URL] 🠔
  4. [7]7. Harris SB, Stewart M, Brown JB, Wetmore S, Faulds C, Webster-Bogaert S, et al. Type 2 diabetes in family practice. Room for improvement. Can Fam Physician. 2003;49(6):778-85. 🠔
  5. [8]8. Harris S, Yale JF, Dempsey E, Gerstein H. Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Can Fam Physician. 2008;54(4):550-8. 🠔
  6. [9]9. Gagliardino JJ, Costa-Gil JE, Faingold MC, Litwak L, Fuente GV. Insulina y control de la diabetes en la Argentina. Medicina (B Aires). 2013;73(6):520-8. 🠔
  7. [10]10. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek F, Matthews DR, et al Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-9. http://doi.org/bb4bxn. [URL] 🠔
  8. [11]11. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metabc Disord. 2002;26(Suppl 3):S18-24. http://doi.org/fdzfzv. [URL] 🠔
  9. [12]12. Funnell MM. Overcoming barriers to the initiation of insulin therapy. Clinical Diabetes. 2007;25(1):36-8. http://doi.org/d4c5gj. [URL] 🠔
  10. [13]13. Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord. 2012;11(1):17.http://doi.org/qnp. [URL] 🠔
  11. [14]14. Shah BR, Hux JE, Laupacis A, Zinman B, Van Walraven C. Clinical inertia in response to inadequate glycemic control do specialists differ from primary care physicians? Diabetes Care. 2005;28(3):600-6. http://doi.org/cps7t2. [URL] 🠔
  12. [15]15. Cox AR, Ferner RE. Prescribing errors in diabetes. British Journal of Diabetes and Vascular Disease. 2009;9(2):84-8. http://doi.org/fw554v. [URL] 🠔
  13. [16]16. Faus-Dáder MJ, Martínez-Romero F. La Atención Farmacéutica en farmacia comunitaria: evolución de conceptos, necesidades de formación, modalidades y estrategias para su puesta en marcha. Pharm Care Esp. 1999;1:52-61. 🠔
  14. [17]17. American Diabetes Assciation. 1. Promoting Health and Reducing Disparities in Populations. Diabetes Care. 2017;40(Suppl 1):S6-S10. http://doi.org/cp7x. [URL] 🠔
  15. [18]18. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2017 Executive Summary. Endocrine Practice. 2017;23(2):207-38. http://doi.org/f9zxms. [URL] 🠔
  16. [19]19. Home P, Riddle M, Cefalu WT, Bailey CJ, Bretzel RG, del Prato S, et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care. 2014;37(6):1499-508. http://doi.org/f564fk. [URL] 🠔
  17. [22]22. Petznick A. Insulin management of type 2 diabetes mellitus. Am Fam Physician. 2011;84(2):183-90. 🠔
  18. [23]23. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract. 2016;22(1):84-113. http://doi.org/f8rhgj. [URL] 🠔
  19. [25]25. Campos C. Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae. Postgrad Med. 2012;124(6):90-7. http://doi.org/f4ndxj. [URL] 🠔
  20. [26]26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89. http://doi.org/bcp5tv. [URL] 🠔
  21. [27]27. Maedler K, Donath MY. β-Cells in type 2 diabetes: a loss of function and mass. Horm Res. 2004;62(Suppl 3):67-73. http://doi.org/fqqmf4. [URL] 🠔
  22. [28]28. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on p-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-60. http://doi.org/fksjwc. [URL] 🠔
  23. [29]29. Villegas-Perrasse A, Abad SB, Faciolince S, Hernández N, Maya C, Parra L, et al. El control de la diabetes mellitus y sus complicaciones en Medellín, Colombia, 2001-2003. Rev Panam Salud Pública. 2006;20(6):393-402. http://doi.org/dw7nxp. [URL] 🠔
  24. [30]30. Machado-Alba JE, Moncada-Escobar JC, Mesa-Escobar G. Patrones de prescripción de antidiabéticos en un grupo de pacientes colombianos. Rev Panam Salud Pública. 2007;22(2):124-31. 🠔
  25. [31]31. Pellegrini F, Belfiglio M, De Berardis G, Franciosi M, Di Nardo B, Greenfield S, et al. Role of organizational factors in poor blood pressure control in patients with type 2 diabetes: the QuED Study Group-quality of care and outcomes in type 2 diabetes. Arch Intern Med. 2003;163(4):473-80. http://doi.org/bp8tm8. [URL] 🠔
  26. [33]33. Alba LH, Bastidas C, Vivas J, Gil F. Prevalencia de control glucémico y factores relacionados en pacientes con diabetes mellitus tipo 2 del Hospital Universitario de San Ignacio, Bogotá, Colombia. Gac Med Mex. 2009;145(6):469-74. 🠔
  27. [34]34. Mavrogiannaki AN, Migdalis IN. Long-acting basal insulin analogs: latest developments and clinical usefulness. Ther Adv Chronic Dis. 2012;3(6):249-57. http://doi.org/f4jg6n. [URL] 🠔
  28. [35]35. Mancera-Romero J, Hormigo-Pozo A, Fernández-Arquero J, Baca-Osorio A, Aparicio-Cervantes M, Muñoz-González L. Utilización de fármacos hipoglucemiantes en el ámbito de la atención primaria de Málaga durante los años 2008-2012. SEMERGEN-Medicina de Familia. 2014;40(1):4-11. http://doi.org/f2nqbj. [URL] 🠔
  29. [36]36. Peralta-Pedrero ML, Valdivia-Ibarra FJ, Hernández-Manzano M, Medina-Beltrán GR, Cordero-Guillén MA, Baca-Zúñiga J, et al. Guía de práctica clínica. Prescripción farmacológica en el adulto mayor. Rev Med Inst Mex Seguro Soc. 2013;51(2):228-39. 🠔
  30. [37]37. Harper W, Clement M, Goldenberg R, Hanna A, Main A, Retnakaran R, et al. Pharmacologic management of type 2 diabetes. Can J Diabetes. 2013;37(Suppl 1):S61-8. http://doi.org/cp77. [URL] 🠔
  31. [38]38. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57(539):455-60. 🠔
  32. [39]39. UK Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care. 1998;21(1):87-92. http://doi.org/d3drb4. [URL] 🠔

Authors
Llinás-Castro, R., Alvis-Estrada, L., & Durán-Lengua, M.
Affiliations
Universidad de Cartagena (CO)
Venue
Revista de la Facultad de Medicina
Publisher
Universidad Nacional de Colombia
Published
2018-10-01
Volume
66
Issue
4
Pages
551-555
ISSN
  • 0120-0011 (ISSN-L)
  • 2357-3848
DOI
10.15446/revfacmed.v66n4.58933
OpenAlex
W2908103699
Cited by
5
References
33
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1
FWCI
0.20
Type
journal article
Language
en
Open access
Licence
Locations
  • Revista de la Facultad de Medicina (publishedVersion, cc-by)
  • Magazine Portal Bibliotech Digital (Universidad Nacional de Colombia) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Redalyc (Universidad Autónoma del Estado de México) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
clinical inertia, insulin prescription, type 2 diabetes, long-acting insulin analogues, medication use, primary care, diabetes management, glycemic control

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review